We focused on the DNA damage response protein MRE11 (Fig. 2D) because this protein was the only one that is directly druggable [11], it is not previously known to be regulated by OGT, it is overexpressed in the aggressive prostate cancer [47], and, as discussed in the introduction, DNA damage response is remodeled in the CRPC [42]. The gene discussed is MRE11; the disease is prostate carcinoma.